Sunday, February 9, 2025

Partnership Extended: Genomics plc and Vertex Pharmaceuticals Collaborate on Precision Medicine

Similar articles

Partnership in scientific research is a powerful catalyst for innovation, and Genomics plc’s recent extension of its collaboration with Vertex Pharmaceuticals Incorporated exemplifies this potential. The two companies have agreed to continue their partnership for an additional three years, leveraging machine learning to study the human genome and develop new and improved precision medicines. This collaboration, which began in 2018, aims to harness genomic insights to drive advancements in drug development.

In a press release, Vertex’s senior vice president and head of global research, Mark Bunnage, expressed his enthusiasm: “Vertex’s leading-edge discovery teams and R&D capabilities, and Genomics’ world-class scientists, are at the forefront of using insights into human genetics to identify the most promising targets and advance them into medicines for patients. This collaboration has been valuable and productive, and we’re excited to continue and expand our transformative work right across the drug development pathway.”

Subscribe Weekly Market Access News

* indicates required

Partnership Extended: Genomics plc and Vertex Drive Precision Medicine Forward

Professor Sir Peter Donnelly FRS, CEO and founder of Genomics plc, echoed this sentiment: “We are proud to extend our partnership with Vertex once again. Our unique genomic data platform has meant that together, we have discovered novel genetically-validated targets with the potential to address diseases of high unmet medical need. Vertex is rightly recognized for its innovative pipeline and track record in developing treatments for serious diseases, which benefit the patients, families, and healthcare systems coping with these often life-threatening conditions. We are delighted to continue working with them to drive precision medicine approaches where treatments are tailored and delivered to those most likely to benefit.”

This partnership is not the only collaborative effort that Genomics plc has undertaken. In April, the company announced a new collaboration with GSK to research the use of polygenic test scores (PRS) for patient selection in clinical trials and other applications. This collaboration aims to optimize clinical trial design by using PRS to identify the most suitable participants, potentially reducing trial size and duration, and improving the efficiency of drug development.

Regarding this collaboration, Donnelly stated, “We could not be more excited to be collaborating with GSK on this program. PRS-based approaches have the potential to support clinical trial design. Using PRS to get the right people into studies could have a potential positive impact, including in the reduction of trial size and timescale, leading to efficiencies in drug development.”

Partnership

Partnership Advances: Genomics plc and GSK Explore PRS in Clinical Trials

Robert Scott, vice president of human genetics and genomics at GSK, added, “Genomics plc is leading in both the development and real-world application of PRS-based approaches, opening up new frontiers in genomic medicine. At GSK, we have demonstrated the opportunity for genetics to guide drug discovery and development; I look forward to working with Genomics plc to further explore the potential for PRS to support clinical trial design.”

Genomics plc is also making strides in integrating genomic research into the health insurance industry. The company has expanded its partnership with MassMutual to help policyholders utilize genomic research for more informed health decisions. This collaboration aims to provide individuals and their doctors with precise information about specific health risks, enabling proactive and preventative health measures.

Donnelly highlighted the significance of this partnership: “While the study of genomics is not new, it now provides an enormous opportunity to help individuals live their longest, healthiest lives. By giving individuals and their doctors much more precise information about the particular health risks they face, they can take the right actions, at the right time, to help prevent disease entirely, or to catch it early when outcomes are much better. As a leader in insurance, MassMutual is one of the first to understand the untapped value genomics brings in making proactive and preventative health choices. We’re thrilled to work alongside a partner aligned with our mission of transforming health and making this technology more widely available.”

Overall, the extended partnership between Genomics plc and Vertex Pharmaceuticals is a testament to the power of collaboration in advancing precision medicine. By combining their expertise and resources, these companies are well-positioned to make significant strides in the development of targeted treatments for diseases with high unmet medical needs. As they continue their work, the potential benefits for patients, healthcare systems, and the broader medical community are substantial.

You can follow our news on our Telegram, LinkedIn and Youtube accounts.

Partnership in scientific research is a powerful catalyst for innovation, and Genomics plc’s recent extension of its collaboration with Vertex Pharmaceuticals Incorporated exemplifies this potential. The two companies have agreed to continue their partnership for an additional three years, leveraging machine learning to study the human genome and develop new and improved precision medicines. This collaboration, which began in 2018, aims to harness genomic insights to drive advancements in drug development.

Resource: Pr News Wire, July 17, 2024


This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article